Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

(2012) M. Gupta et al.   BLOOD

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma

(2011) A. Scuto et al.   CANCER RESEARCH

BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

(2011) J. Iqbal et al.   CLINICAL CANCER RESEARCH

H+-myo-Inositol Transporter SLC2A13 as a Potential Marker for Cancer Stem Cells in an Oral Squamous Cell Carcinoma

(2011) D. G. Lee et al.   CURRENT CANCER DRUG TARGETS

Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival

(2011) Juan Martín Arriaga et al.   HUMAN PATHOLOGY

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma

(2011) Wu ZL et al.   Journal of Hematology & Oncology

Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy

(2011) M Gupta et al.   LEUKEMIA

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma

(2010) R. Shaknovich et al.   BLOOD

ARF-dependent regulation of ATM and p53 associated KZNF (Apak) protein activity in response to oncogenic stress

(2010) Shan Wang et al.   FEBS LETTERS

STAT3 tyrosine phosphorylation influences survival in glioblastoma

(2010) Peter Birner et al.   JOURNAL OF NEURO-ONCOLOGY

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy

(2009) W. W.L. Choi et al.   CLINICAL CANCER RESEARCH

MEME SUITE: tools for motif discovery and searching

(2009) T. L. Bailey et al.   NUCLEIC ACIDS RESEARCH

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3

(2008) E. A. Nelson et al.   BLOOD

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events

(2008) C. Nardella et al.   GENES & DEVELOPMENT

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

(2008) Kai Fu et al.   JOURNAL OF CLINICAL ONCOLOGY

STAT3 expression in gastric cancer indicates a poor prognosis

(2008) Dae-Young Kim et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

(2008) Michael Pfreundschuh et al.   LANCET ONCOLOGY

HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer

(2008) Krishan K. Rasiah et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compensatory IKK  activation of classical NF- B signaling during IKK  inhibition identified by an RNA interference sensitization screen

(2008) L. T. Lam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

(2008) G. Lenz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma

(2007) L. T. Lam et al.   BLOOD